Biosensors   

Is Biosensors a good buy?

Investor, you are always very   sharp and   knowledgeable. Wonder why this is not reported in the SGX?

investor      ( Date: 08-Jul-2011 15:13) Posted: Morges, Switzerland, 7 July 2011 – Biosensors International has received approval for reimbursement in France for its BioMatrix Flex™ drug-eluting stent system. The addition of BioMatrix Flex to the LPPR (“Liste des Produits et Prestations Remboursables”) was published in the Journal Official on 22 June 2011. As a result of this announcement, BioMatrix Flex is now available to patients with coronary artery disease throughout France. “We are delighted to have obtained reimbursement in France - the largest market for drug-eluting stents in Europe - for BioMatrix Flex”, commented Biosensors Co-CEO Jeffrey B. Jump. “French authorities have a particularly rigorous review process and will only grant reimbursement to a product which can clearly demonstrate both clinical and economic benefits. This is further recognition for the growing body of clinical evidence that supports our innovative technology.” Read more: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=43827#ixzz1RUmwJeAN For Information.

 

Testing 2 or 3 times at $1.37, looks like coming any time.

 

 

All these price movements due to analyst's reports???? 

 

Biosensors International Group: Market share gains to continueBy Andy Wong
Wed, 6 Jul 2011, 09:09:27 SGT

http://www.ocbcresearch.com/pdf_reports/company/Biosensors-110706-OIR.pdf

 

Good, vest this morning $1.34, wait for more upside.

 

Biosensors International Group: Market share gains to continue

From big four to big three in DES market.

International Group (BIG) could potentially benefit from recent news that

Johnson & Johnson (J& J) is exiting the drug-eluting stent (DES) market by

end 2011. While J& J's market share is up for grabs, we believe that

competition will be intense as other big players such as Boston Scientific

and Abbott Laboratories will be aggressively seeking to increase their sales.

Moreover, J& J's market share had been steadily declining over the years

(Exhibit 1). One disadvantage for BIG is that it has not penetrated the U.S.

DES market yet, which is currently the largest market in the world. J& J's

DES sales in the U.S. formed 33.8% of its overall DES revenue in FY10.

Nevertheless, we expect BIG to further increase its penetration rates in

other regions as a result of J& J's withdrawal. BIG had highlighted during its

FY11 teleconference call that it is growing at six times of what the overall

market is growing, which implies that BIG was already capturing market

share from its competitors prior to J& J's announcement. Future growth

would be supported by additional positive clinical trial data, coupled with

the introduction of new DES products such as the Axxess bifurcated DES

and BioFreedom.We believe that Biosensors

All the right moves.

at BIG have been positive, notwithstanding the dilutive impact from the new

placement of shares to fund future growth. These stem from (i) Terumo

Corp obtaining approval for the Nobori DES to be sold in Japan, which

would increase BIG's licensing revenues (ii) strategic investments by

boutique funds, which is in-line with BIG's strategy to increase its focus in

China and (iii) acquisition of the remaining 50% stake in JW Medical

Systems (JWMS), one of the three largest local players in the Chinese

DES market.In our opinion, recent corporate developments ongoing

Maintain BUY.

opportunity for BIG to enhance its reputation as a DES player. However, we

have already accounted for strong market share gains in our assumptions

and hence are retaining our estimates. We believe that continued penetration

in new geographical markets and existing ones would underpin BIG's

earnings trajectory ahead. BIG's next re-rating catalyst could come from

obtaining approval from China's State Food and Drug Administration for its

BioMatrix family of DES. We understand that progress is being made and

approval could be imminent, given positive clinical trial results and China's

rising demand for stent treatments. Our DCF-based fair value estimate of

S$1.60 implies a potential upside of 19.0%. Reiterate

Ching Andy)We view J& J's exit from the coronary stent market as anBUY.(Wong Teck

 

Nomura :

Raising price target

Positioned for growth

Action: Raising TP following JWMS acquisition

Biosensors’ proposed acquisition of the 50% stake in JWMS from Shangdong Weigao is a win-win for both parties, in our view. With full control, Biosensors will be able to pursue a more aggressive strategy in China, while Weigao will emerge as a major shareholder, benefitting from Biosensors’ intellectual property and global footprint. We reduce our EPS estimates by 12% and 15% for FY12F and FY13F, respectively, due to dilution from share issuance but raise our price target to SGD1.59 to reflect a higher valuation for JWMS and the rest of its franchise.

Catalyst: Japan will likely be the key driver in FY12F

Biosensors should benefit significantly from the imminent launch of Nobori in Japan by its licensee Terumo. The revenue share arrangement will be a key driver for Biosensors in FY12F and FY13F, we expect. The withdrawal of Johnson & Johnson from the DES space will, we believe, allow Biosensors to gain share. We see Biosensors embarking on M& A to further consolidate its position, while venturing into product adjacencies. The pending approval of Biomatrix in China will strengthen JWMS’ product offering in China.

Valuations: Trading below our SOTP-derived PT of SGD1.59

Biosensors is trading below our sum-of-the-parts valuation of SGD1.59. Its current P/E valuation of 20.3x and 12.6x for FY12F and FY13F, respectively, is undemanding given strong growth prospects and enhanced balance sheet.

 

 

Market Pulse: Biosensors

FOCUS

Biosensors International Group: Market share gains to continue

Summary: We believe that Biosensors International Group (BIG) is set for further market share gains, especially following Johnson & Johnson’s (J& J) intention to exit the drug-eluting stent (DES) market, although competition will be intense. We expect BIG’s earnings trajectory to be supported by additional positive clinical data and new product launches. Recent corporate developments have also been positive, in our view, notwithstanding the dilutive impact from the placement of new shares. These stem from (i) Terumo Corp obtaining approval for the Nobori DES to be sold in Japan, which would increase BIG’s licensing revenues (ii) strategic investments by boutique funds and (iii) acquisition of the remaining 50% stake in JW Medical Systems (JWMS). We are retaining our estimates as we have already accounted for strong market share gains in our assumptions. BIG’s next re-rating catalyst is likely to come from obtaining approval from China’s State Food and Drug Administration for its BioMatrix family of DES. Our DCF-based fair value estimate of S$1.60 implies a potential upside of 19.0%. Reiterate BUY. (Wong Teck Ching Andy)

 

I love Biosensors.

Currently, my 3rd best performing counter.

My TP is $1.40.

 

1.315? typo error?.Today volume is healthy .

bishan22      ( Date: 05-Jul-2011 15:45) Posted: Closed book at 1.315. Good luck.  bishan22      ( Date: 14-Jun-2011 09:24) Posted: Up up and away. Good luck. Vested small.

 

Closed book at 1.315. Good luck. 

bishan22      ( Date: 14-Jun-2011 09:24) Posted: Up up and away. Good luck. Vested small.  bishan22      ( Date: 13-Jun-2011 10:09) Posted: Strong buying up today.

 

Boston Scientific Corp. (NYSE:BSX) could be positioned to gobble up some two-thirds of the business left on the table by Cordis Corp. in the U.S., according to research released by the Millennium Research Group.

The market research company said that Johnson & Johnson (NYSE:JNJ) subsidiary Cordis was already seeing serious erosion in its market share for a number of years and was facing even more competition when it decided to pull out of the stent game game altogether.

" Cordis has seen its market share erode over the last number of years," Millennium analyst Karene Dumoulin said in a prepared release. " Between 2009 and 2010 Cypher's contribution to Cordis' worldwide revenues dropped from 34 percent to 24 percent, and would likely have fallen below 20 percent in 2012. New stents are expected in all geographies in the next year. This is an extremely active and competitive market. Physicians look for clinical results and show little product loyalty. You're only as good as your last product."

Boston Scientific is the most likely to pick up the slack from Cordis in the U.S., according to Millennium to the tune of about two-thirds of the market, while Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) fight each other for the rest.

Millennium said the Japanese-based Terumo Medical Corp. will take two-thirds of Cordis share in the land of the Rising Sun, while the remainder will be divided between Abbott and Boston Scientific.

BSX CEO J. Raymond Elliott recently called the Cordis decision " an upside for 2012" for the Natick, Mass.-based stent maker.

" If you look at the size of the markets, the Cordis portion is probably about $400 million or so," he said. " However, the part people are missing is that there's another $400 million market in guides, bare metal, diagnostics and so on. It's tougher to get at but it's there. It's a rare gift… You don't get opportunities like that very often, so we're doing what we need to do to get that business."

 

It is highly probable for it to reach that price,

  and even beyond... The question of how it will

      wriggle before it finally reaches that level,

                    no one can tell... and that is the

                            problematic and nail-biting part.

                                    Of course it may also head straight up...

catalyst      ( Date: 30-Jun-2011 23:21) Posted: Hitting previous high of around 1.40 shoud be achievable. My opinion.

 

Hitting previous high of around 1.40 shoud be achievable.

My opinion.

 

OCBC Investment Research in a June 14 research report says: " Biosensors International Group (BIG) has proposed to acquire the remaining 50% stake in JW Medical Systems (JWMS) from Shandong Weigao Group Medical Polymer (Shandong Weigao).

" We believe that this move would help to support BIG's earnings momentum moving forward. Management estimates that this acquisition would be completed by the later part of the year (assuming shareholder approval is obtained), implying that JWMS is likely to be consolidated from 2H12 onwards.

" We take into account the dilutive impact caused by the enlarged share base and also update our required return on equity assumption to 9.1%. Fair value estimate increases from $1.55 to $1.60. MAINTAIN BUY."

 

From a technical perspective, Biosensors is potentially forming a inverted head and shoulders pattern, with the neckline at 1.32.

A successful break above 1.32 will confirm this pattern, and the equis-distant move from this breakout is approximately 10 cents, based on the distance between the head and neckline.

Please note - Not all patterns fulfill their theoretical objective, and not all patterns are successful..

A personal observation.  Not a call to buy/sell.

 

May be some news.... always come in the midst of down market.   Never fails..

bishan22      ( Date: 29-Jun-2011 11:35) Posted: Wow... today BB taking turn to ramp up this counter.  bishan22      ( Date: 14-Jun-2011 09:24) Posted: Up up and away. Good luck. Vested small.

 

Wow... today BB taking turn to ramp up this counter. 

bishan22      ( Date: 14-Jun-2011 09:24) Posted: Up up and away. Good luck. Vested small.  bishan22      ( Date: 13-Jun-2011 10:09) Posted: Strong buying up today.

 

Hony Capital eyes U.S. and European firms By Stephen Aldred and Lee Chyen Yee HONG KONG | Thu Jun 16, 2011 7:27am EDT (Reuters) - Chinese private equity fund Hony Capital, sponsored by Legend Holdings CNASCA.UL, is looking to take leading U.S. and European technology companies into China to increase their value. Hony, among the most successful private equity funds in China, also hopes to raise a fifth U.S. dollar fund at no less than the $1.4 billion size of its fourth, CEO and managing partner John Zhao said on Thursday. "There's a lot of great technology companies out of Silicon Valley, out of Europe, out of Japan, Germany, that if they could get their technology or product quickly pushed into the Chinese market they will be many times more valuable," he told Reuters. The first step to increasing value, and penetration of China, is to change the mindset of a company board so it does not see the country purely as an export market, he said. Zhao said Hony's role with these companies is to use its expertise in China to increase penetration of the market. "Many companies will not do that successfully if ... the board just visit once or twice a year," he said in an interview after a company event. Zhao said Hony's investment last year in Singapore-listed Biosensors International Group Ltd (BIOS.SI) is an example of the kind of deal he hopes to repeat. Hony bought 30 percent of Biosensors and took a board seat. "We're going to do more of these," said mainland-born Zhao, a graduate of the Kellogg School at Northwestern University's MBA program. Zhao also said Hony Capital, which raised one of China's first market-driven private equity funds in 2003, will begin raising its fifth U.S. dollar fund before the end of 2011. He said the fund would be no smaller than Hony's last dollar fund, which raised $1.4 billion in 2008, adding only that it will approach existing investors. Hony's previous investors include the Bill and Melinda Gates Foundation, California State Teachers Retirement System, Canada Pension Plan Investment Board, Goldman Sachs (GS.N) Asia LLC, and Singapore sovereign wealth fund Temasek Holdings Pte Ltd TEM.UL. The firm has raised four U.S. dollar funds and two yuan funds, and has around $4.4 billion assets under management, according to a source familiar with the matter.